AVIA Releases OTT Study in Singapore at its First OTT Upfront Showcase Presenting Premium Content at its Best ACN Newswire

AVIA Releases OTT Study in Singapore at its First OTT Upfront Showcase Presenting Premium Content at its Best

Singapore, Sep 12, 2022 - (ACN Newswire via SEAPRWire.com) - The Asia Video Industry Association (AVIA) has released a new research study entitled Premium OTT - Building its Rightful Place in the Digital Market, to understand the usage of different video services in Singapore and attitudes towards them. The independent research study conducted by Milieu Insight was unveiled to agencies, advertisers and brands at AVIA's first OTT Upfront Showcase where two of the region's top premium video services, iQIYI and Viu, presented previews and highlights of their upcoming slate of content to the audience at a closed-door event. The research shows that Premium OTT streaming services (OTT) are clearly differentiated from videos viewed on social media or video sharing sites. OTT was highly valued by consumers in Singapore for having the highest quality content. 58% of respondents indicated that they felt premium OTT services had high quality content, compared to only 36% for social media and video sharing services. Similarly, when asked which video services they generally felt captured the highest levels of attention while watching, 49% of respondents selected OTT streaming services, compared to only 35% who selected social media and video sharing services. Levels of engagement were also entirely different with 51% of people feeling immersed when watching OTT content as opposed to only 39% for social media & video sharing. Top emotions elicited when watching OTT were happiness and amusement whereas for social media and video sharing, the top emotion was "nothing". When looking at the impact of advertising, linear television remains the place where it is most noticed (76%) and ads are thought to be the highest quality (41%), although it is in social media where ads feel most intrusive (37%). Linear was again the winner when it came to prompting brand or product searches (25%) and prompting purchase (19%). Louis Boswell, CEO, AVIA, commented that this "Bodes well for the OTT industry. There is a clear link between linear television and OTT from a content perspective, and with more OTT services looking at advertising, I strongly suspect it is simply a matter of time before the effectiveness of ads on OTT matches that of linear television." Dinesh Ratnam, Country Manager, Singapore, Malaysia and Brunei, iQIYI International, commented, "AVIA's research further cements the rise of OTT and the appreciation for the premium content on OTT platforms. As the OTT industry continues evolving and becoming more accessible, its audience is also looking for more diverse content. With the global success of shows such as iQIYI's original costume drama Story of Yanxi Palace drawing a global audience larger than that of Game of Thrones, the rise of Asian content is also drawing in larger, more diverse audiences. We are thrilled to be a part of AVIA's inaugural OTT Upfront Showcase in Singapore and to have the opportunity to showcase our exciting slate to advertisers and partners."AVIA thanks its members Magnite, PubMatic, The Trade Desk, and Xandr for supporting the OTT Upfront Showcase and the same companies plus Index Exchange for supporting the research. A link to the research study entitled Premium OTT - Building its Rightful Place in the Digital Market can be downloaded here (https://bit.ly/3L4lrMD). About the Premium OTT StudyThe study, Premium OTT - Building its Rightful Place in the Digital Market, was conducted in Singapore by Milieu Insight Pte Ltd, with online fieldwork using Milieu Insight's online panel. The sample size was n=1200 and was representative of the Singapore adult population aged 16+. Premium OTT Services listed in the study were as follows: Amazon Prime, Apple TV+, Disney+, HBO Go, iQIYI, meWATCH, Netflix, Singtel Cast, StarHub TV+, Viu and WeTV. Social Media and Video Sharing Services listed were: Daily Motion, Facebook, Instagram, Snapchat, Telegram, TikTok, Twitter, Vimeo, WhatsApp and YouTube. About the Asia Video Industry AssociationThe Asia Video Industry Association (AVIA) is the trade association for the video industry and ecosystem in Asia Pacific. It serves to make the video industry stronger and healthier through promoting the common interests of its members. AVIA is the interlocutor for the industry with governments across the region, leads the fight against video piracy through its Coalition Against Piracy (CAP) and provides insight into the video industry through reports and conferences aimed to support a vibrant video industry. For media enquiries and additional background please contact:Charmaine KwanHead of Marketing and CommunicationsEmail: charmaine@avia.orgWebsite: www.avia.orgLinkedIn: www.linkedin.com/company/asiavideoiaTwitter: @AsiaVideoIA Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
EC Healthcare Chairman Mr. Eddy Tang Further Increases Shareholding, Exhibiting Unwavering Assurance in the Future Development of the Group ACN Newswire

EC Healthcare Chairman Mr. Eddy Tang Further Increases Shareholding, Exhibiting Unwavering Assurance in the Future Development of the Group

HONG KONG, Sep 9, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that on 7 September 2022, the Group's Chairman, Executive Director and Chief Executive Officer Mr. Tang Chi Fai further acquired a total of 170,000 shares of the Company on the open market for approximately HK$854,800 at an average price of HK$5.0282 per share. Prior to this transaction, Mr. Tang had already increased his shareholding in the Company earlier this month on 1 September 2022, acquiring a total of 107,000 shares at an average price of $5.4905 per share. After the transaction, Mr. Tang holds an aggregate of 722,204,610 shares in the Company, increasing his equity stake from 61.27% to 61.29%.Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "In spite of the current economic climate, we are confident that the medical market will remain resilient and that long-term public-private healthcare partnerships will continue to drive up investment in Hong Kong's private healthcare sector. Reaping the benefits from its ongoing investments in elevating healthcare service offerings, the Group exemplified solid business recovery by delivering first-quarter sales volume of no less than HK$860 million for the financial year that concluded on March 31, 2023. Management is still nevertheless upbeat about the Group's business success going forward. In order to continue enhancing EC Healthcare's enclosed healthcare ecosystem, the Group will go forward with its close collaboration with the major players in the technology, telecommunications, insurance, property, and pharmaceutical industries."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre EC DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
EC Healthcare and AXA Jointly Establish the FIRST AXA Medical Centre ACN Newswire

EC Healthcare and AXA Jointly Establish the FIRST AXA Medical Centre

HONG KONG, Sep 8, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group has entered into a non-legally binding memorandum of understanding (the "MOU") with AXA Hong Kong & Macau ("AXA") for a strategic partnership, pledging to work together to provide premium and comprehensive health management services to customers. EC Healthcare and AXA signed Memorandum of understanding today to kick start their long term collaboration. (From left: Emily Li, Chief Employee Benefits & Wellness Officer, AXA Hong Kong and Macau, Sally Wan, Chief Executive Officer of AXA Greater China, Eddy Tang, Founder, Chairman, Executive Director and CEO of EC Healthcare and Leslie Lu, Executive Director and Co-CEO of EC Healthcare)Under the partnership, the first AXA Medical Centre was unveiled today on the 34th floor of the World Trade Centre in Causeway Bay. Together with the AXA designated Endoscopy and Day Surgery Centre in Central, it will officially start operating in November this year.Located in the central business district of Causeway Bay, the AXA Medical Centre occupies a floor area of over 5,000 sq. ft. The center offers services include preventive medicine, body checks, vaccinations, and nutritional counselling with support from on-site medical professionals including general practitioners, Chinese medicine practitioners, dieticians and radiographers. The AXA Medical Centre provides various body check services such as chest and abdominal X-rays, ultrasound scans, gynaecological examination, electrocardiogram (ECG) with over 10 body examination rooms. Other services include allergy tests, non-invasive genetic screening tests for colorectal cancer, and all pre-insurance health screening for AXA customers.EC Healthcare is building a one-stop, multi-disciplinary, enclosed healthcare service platform, which allows AXA's customers to obtain a seamless medical referral service after check-ups and enjoy comprehensive, high-quality medical services that covers multiple medical disciplines.In addition to setting up dedicated medical centres, the Group and AXA will further their cooperation with a view to extending the market coverage of their services to other central business districts and residential areas.Mr. Leslie Lu, Executive Director and Co-CEO of EC Healthcare said, "Hong Kong's private healthcare market has huge potential. The Group regards strategic partnership with insurance firms as a key strategy of building up its presence in the growing market. The Group is very honoured to form partnership with such an internationally leading insurance group as AXA. The Group believes that the strategic partnership will boost higher customer public traffic with strong synergy in the healthcare sector and enhance the organic growth of the Group's medical and healthcare business through the provision of high-quality and high-end branding medical and healthcare services. The Group will also forge ahead with its deep strategic cooperation with the key players in the technology, telecommunications, insurance, property and pharmaceutical industries so as to keep enriching EC Healthcare's enclosed healthcare ecosystem."Ms. Sally Wan, Chief Executive Officer of AXA Greater China said, "AXA Medical Centre marks a major milestone for us in delivering exceptional health management services to our customers, providing our customers with all-round care across their life stages. The centre, offering comprehensive one-stop health management services spanning prevention, diagnosis, and treatment, not only enhanced AXA's health management ecosystem but also brought to life our ongoing commitment to become a lifelong partner to our customers. AXA and EC Healthcare share the same vision of improving our customers' holistic wellness. Through this partnership, we can bring an exclusive, innovative, and personalised healthcare experience beyond insurance to our customers leveraging our combined strength."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk Tel: (852) 2136 6952 / 2169 0467 Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
EC Healthcare Chairman Mr. Eddy Tang Increases Shareholding, Demonstrating Full Confidence in the Group’s Future Development ACN Newswire

EC Healthcare Chairman Mr. Eddy Tang Increases Shareholding, Demonstrating Full Confidence in the Group’s Future Development

HONG KONG, Sep 2, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that on 1 September 2022, the Group's Chairman, Executive Director and Chief Executive Officer Mr. Tang Chi Fai had acquired a total 107,000 shares of the Company on the open market for approximately HK$587,000 at an average price of HK$5.4905 per share. After the transaction, Mr. Tang holds an aggregate of 722,034,610 shares in the Company, increasing his equity stake from 61.26% to 61.27%.Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "Benefitting from the result of its continuous investment in IT, brand and service, the Group recorded a sales volume of no less than HK$860 million in the first quarter of the financial year ended 31 March 2023 (April to June 2022). This shows a good recovery in its business. EC Healthcare will continue to consolidate the healthcare market through organic growth and acquisitions and thus reinforce its leading market position. The Group believes that the medical market will remain resilient in the challenging business environment and that public-private partnerships in healthcare will keep boosting spending in the market of Hong Kong's private healthcare sector in the long run. Looking ahead, the management remains optimistic about the Group's business performance. The Group will also forge ahead with its deep cooperation with the key players in the technology, telecommunications, insurance, property, and pharmaceutical industries so as to keep enriching EC Healthcare's enclosed healthcare ecosystem."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre EC DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine IpTel: (852) 2136 6952 / 2169 0467 / 3920 7649Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
VC Holdings Announces 2022 Interim Results ACN Newswire

VC Holdings Announces 2022 Interim Results

HONG KONG, Aug 31, 2022 - (ACN Newswire via SEAPRWire.com) - Value Convergence Holdings Limited ("VC Holdings", together with its subsidiaries, the "Group"; Stock Code: 0821.HK), a well-established and one-stop financial services institution in Hong Kong, is pleased to announce its unaudited interim results for the six months ended 30 June 2022 ( the "Reporting Period"). The Group tirelessly pursued opportunities to diversify its business during the Reporting Period, and expanded its digital asset business with good progress. During the Reporting Period, the recurrent outbreaks of COVID-19, coupled with persistently high inflation and conflict between Russia and Ukraine, posed unprecedented challenges to the global economy, intensifying uncertainty in the global and Hong Kong financial markets. The Group's consolidated revenue from continuing operations decreased by 6.0% year-on-year to approximately HK$35.7 million. Due to the increase in net realised and unrealised loss in financial assets at fair value through profit or loss, and the impairment loss on accounts receivable and other receivables, the consolidated loss for the period attributable to shareholders amounted to approximately HK$61.8 million (1H2021: profit for the period attributable to shareholders of HK$101.1 million). Basic loss per share from continuing and discontinued operations was HK2.97 cents (1H2021: Basic earnings per share from continuing and discontinued operations of HK5.93 cents). Mr. Peter Fu, Chairman and Executive Director of Value Convergence Holdings Limited, "VC Holdings has always been dedicated to offering premier financial services and products that fulfill various investment and wealth management needs of clients in the Great China region. During the first half of 2022, amid the lingering impact of Coronavirus Disease 2019, the global economy continued to struggle with persistent downside risks including escalating geopolitical tensions, growing financial instability and surging inflation, all of which hindered economic growth. The Group's revenue declined due primarily to a reduction in brokerage commission income that was broadly in line with the deterioration of the economic environment and the contraction in transaction volumes in the market overall."Business OverviewFinancial services businessThe financial services business remained the Group's major revenue stream during the Reporting Period and contributed approximately 98% of the Group's total revenue. The business segment recorded a 7% decrease in revenue amid an overall decline in the volume of economic transactions. During the Reporting Period, the Group continued to provide local and overseas securities dealing, derivatives and other structured products trading, placement and underwriting, margin financing through VC Brokerage Limited and VC Futures Limited, and money lending through VC Finance Limited. Besides, the Group offered corporate finance advisory services, including mergers and acquisitions advisory and company secretarial services, through VC Capital Limited ("VC Capital") and VC Corporate Services Limited. During the Reporting Period, VC Capital was appointed as a financial adviser to a number of Hong Kong-listed companies engaged in corporate exercises.Proprietary trading businessThe pronounced slowdown in the global capital market, mainly led by high inflation and interest rate hikes amid the double-whammy of the renewed threat of COVID-19 variants and the Russo-Ukrainian war, resulted in substantial volatility in the local stock market. Aligned with the overall market situation, the Group held equity securities listed in Hong Kong worth approximately HK$414.9 million as financial assets held for trading, marking a 2.0% decrease in the market value as compared with 31 December 2021. Despite the challenges, the Group continued to focus on the fundamentals of its investment targets and will continue actively to pursue long-term capital gains.Sales and marketing of digital assetsTo further expand the newly developed business, VC Holdings continued to push forward expansion in various respects to actively enter the internet-native Generation Z market. The Group has recruited a seasoned team of sales and marketing talents to broaden its sales channels with a view to expediting business development. In addition, the Group has formed strategic cooperation agreements with several leading corporations, such as E-Home Entertainment, to commence in-depth cooperation in the internet industry and jointly carry out integrated market development in various areas, including the Chinese console games market, the expansion of domestic games into overseas markets, and digital marketing. During the Reporting Period, the Group deepened its collaboration with Tencent and became one of the few distributors of Tencent's Q Coins covering a considerable number of provinces in China. Meanwhile, the Group commenced collaboration with the distributor of Microsoft products in Hong Kong in connection with sales of Xbox-related virtual assets. The Group has also begun a collaboration with Xunlei Limited (NASDAQ: XNET) to sell non-fungible tokens. During the Reporting Period, the Group recorded a gross merchandise value of approximately HK$120.0 million, represented by the gross sum of digital assets sold to its customers. OutlookThe uncertain macroeconomic outlook is expected to continuously affect financial stability, resulting in a more volatile stock market. On a positive note, the gradual easing of social distancing measures and a reduction in cross-border transportation disruptions, alongside the stabilization of the local pandemic situation in Hong Kong, will help boost economic activities. The Group remains cautiously optimistic about the outlook for its placing and underwriting business, given that fundraising activities among Hong Kong-listed companies is expected to resume gradually. It seeks to expand the scale of its financial services business and continue to identify suitable acquisitions and investment targets in the market as opportunities arise.The Group intends to accelerate the development of digital asset business through digital asset marketing, intellectual property (IP) collaboration and marketing cooperation. To further strengthen its presence and drive synergies between the internet business offered by digital assets and other business segments, more resources have been allocated to further develop the sale and marketing of digital assets to broaden sales channels. The Group will continue to explore and liaise with potential business partners on sales of digital assets and NFTs.Mr. Fu concluded, "Given the huge potential of the digital asset market, we will keep exploring new business opportunities in the mainland China digital asset market, capitalizing on our strategic partnerships and in-depth business collaborations with our allies, namely E-Home Entertainment and Shenzhen Yiyun Information. More resources will be dedicated to mapping out a blueprint for the digital asset segment accordingly. We believe, that the new business will become a new key driver of the Group in the years to come, improving profitability and generating maximum value for all stakeholders."About VC Holdings Limited Value Convergence Holdings Limited (Stock code: 0821.HK) was listed on the GEM board of Hong Kong Stock Exchange in 2001, and completed transfer of listing to the Main Board in 2008. Being a well-established financial services group committed to delivering premier financial services and products in the Great China region, the Group's services include (i) provision of financial services comprising securities and options brokering and dealing, financing services, corporate finance and other advisory services, asset management and insurance brokerage; (ii) proprietary trading; and (iii) sale and marketing of digital assets. For more details, please visit www.vcgroup.com.hk. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
JE Cleantech (JCSE) Announces Results for H1 2022, Revenue of S$7.2 Million and Net Income of S$147,000 ACN Newswire

JE Cleantech (JCSE) Announces Results for H1 2022, Revenue of S$7.2 Million and Net Income of S$147,000

SINGAPORE, Aug 31, 2022 - (ACN Newswire via SEAPRWire.com) - JE Cleantech Holdings Limited (Nasdaq: JCSE), ("the Company") a Singapore-based cleantech company, has announced its financial results for the six months ending 30 June 2022. In its first mid-year update since completing its Nasdaq listing in 2022, the company has seen a decline of 19 per cent in its revenue compared to the corresponding period last year (H1 2021). Net income for the reporting period has been S$147,000, lower than the S$616,000 reported for the first six months of 2021.Speaking about the 2022 results, Ms. Bee Yin Hong, CEO and Founder, JE Cleantech said, "Our industry as with many others was hit hard by the pandemic, but we have weathered it and even achieved impressive growth in one of our key business verticals. We strongly believe in the future to come as we enter the endemic phase and the F&B, travel, and hospitality sectors see rapid recovery. JE Cleantech is well positioned to capture growth opportunities. We are actively widening our product offerings and exploring new markets to bring sustainable returns to our shareholders and investors."The group has been negatively affected by the ongoing disruptions caused by Covid-19, some effects of which may linger post-pandemic such as supply chain disruptions, fluctuations in the cost of raw materials and uneven demand growth from customer groups. Despite this, the Company did not experience any material order cancellations during the reporting period and records an order book value of approximately S$36.8 million as of August 15, 2022.The Company saw a growth of 36 per cent in its provision of centralized dishwashing and ancillary services, compared to the same corresponding period last year, with revenue of S$3.585 million. The company also announced the renewal of a key customer to provide centralized dishwashing services to a fully owned subsidiary of Singapore's leading ground-handling and in-flight catering service provider for a period of three years, starting in September 2022. The contract, which has been closed through its subsidiary, Hygieia Warewashing Pte Ltd., is valued at approximately S$9.3 million (around US$6.7 million). With this renewal, Hygieia Warewashing will have been providing cleaning services for the client for nine years continuously.Having provided centralized dishwashing services in Singapore since 2013, management believes that JE Cleantech is now Singapore's leading manufacturer of precision cleaning systems and provider of centralized dishwashing and ancillary services, with approximately 15 per cent market share in 2020 in terms of revenue (Source: Euromonitor estimates from desk research and trade interviews with leading centralized dishwashing services providers and the relevant trade associations in Singapore). Ms. Hong stated "we believe that JE Cleantech has not only left a strong footprint in Singapore and Malaysia, but has also established a robust network of long-term customers across Southeast Asia, with a growing international footprint in markets such as Europe and the United States."Moving forward, the company is looking to expand its team of R&D staff and engineers, while continuing to strengthen its product portfolio. Recently, it has expanded its scope of service offerings to include tech hardware.About JE Cleantech Holdings LimitedJE Cleantech Holdings Limited is based in Singapore and is principally engaged in (i) the sale of cleaning systems and other equipment; and (ii) the provision of centralized dishwashing and ancillary services. Through its subsidiary, JCS-Echigo Pte Ltd, the company designs, develops, manufactures, and sells cleaning systems for various industrial end-use applications primarily to customers in Singapore and Malaysia. Its cleaning systems are mainly designed for precision cleaning, with features such as particle filtration, ultrasonic or megasonic rinses with a wide range of frequencies, high pressure drying technology, high flow rate spray, and deionized water rinses, which are designed for effective removal of contaminants and to minimize particle generation and entrapment. The Company also has provided centralized dishwashing services, through its subsidiary, Hygieia Warewashing Pte Ltd, since 2013 and general cleaning services since 2015, both mainly for food and beverage establishments in Singapore.Disclaimer: Forward looking statementsThis news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Forward-looking statements may be identified by such words or phrases as "should," "intends," "is subject to," "expects," "will," "continue," "anticipate," "estimated," "projected," "may," "I or we believe," "future prospects," "our strategy," or similar expressions. Forward-looking statements made in this press release that relate to our future contract revenues among other things involve known and unknown risks and uncertainties that may cause the actual results to differ materially from those expected and stated in this announcement. We undertake no obligation to update "forward-looking" statements.For Media Enquiries and Investor Relations, please contact:jcse@preciouscomms.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Yeahka Announces 2022 Interim Results ACN Newswire

Yeahka Announces 2022 Interim Results

HONG KONG, Aug 30, 2022 - (ACN Newswire via SEAPRWire.com) - Yeahka Limited ("Yeahka" or the "Company", Stock Code: 9923), a leading payment-based technology platform in China, is pleased to announce the interim results for the six months ended 30 June 2022 (the "period" or "1H 2022").Financial Highlights-- During the period, the Company's total revenue reached RMB1,641.8 million, representing a year-over-year (YoY) increase of 17.1%. -- Gross profit during the period rose 52.1% YoY to RMB529.3 million, gross margin increased from 24.8% to 32.2%, gross profit contribution from non-payment business was 50%.-- Adjusted EBITDA amounted to RMB69.7million, increased by 39.7% compared with the second half of 2021.-- Gross profit of in-store e-commerce services reached RMB92.3million, gross margin reached 57.1%, increased by 76.9% and 6.6 percentage points respectively, compared with the second half of 2021.Operational HighlightsNumber of users and scale of one-stop payment services continued to grow:-- Total gross payment value ("GPV") of the payment services reached RMB1.06 trillion, up 7.4% YoY;-- The number of active payment service merchants increased 24.1% YoY to a historical high of 7.6 million;-- The number of cities covered exceeded 300 nationwide;-- The number of partnership banks increased to nearly 100; the number of independent sales agents in our network reached nearly 16,000; and the number of application programming interface (API) partners on our cloud payment platform exceeded 3,000.In-store e-commerce services grew rapidly and achieved significant results:-- Total gross merchandise value ("GMV") was nearly RMB1.4 billion, up 17.9 times YoY, and 3.2 times compared with the second half of 2021;-- The number of monthly active users ("MAU") reached 19.0 million; -- The number of paying consumers reached nearly 9.7 million, increasing by 578.9% YoY and 136.0% from the second half of 2021;-- Stock keep units (SKU) reached over 205,300, up 1,570.2% YoY and 39.6% from the second half of 2021;-- Number of regional sites exceeded 300.Steady growth for merchant solutions:-- Number of active merchant solutions merchants increased by 25.8% YoY to nearly 1.5 million.Mr. Luke Liu, Chairman of the Board, Chief Executive Officer and Executive Director of the Company, said, "The resurgence of the COVID-19 pandemic has made 1H 2022 challenging by slowing down retail sales growth of consumer goods, and significantly disrupting offline commerce. But for us, because of our broad coverage across over 300 cities and low geographic concentration, we continued to make progress in scaling up and monetizing our commercial digitalized ecosystem. We have been proactively adapting to the new norm in China's internet industry, by being more cost cautious and profitability-driven, which has been demonstrated by our financial performance in the first half - total revenue and gross margin both showed encouraging improvement year over year("YoY"), particularly with gross profit increasing 52.1% to RMB529.3 million, gross margin improving by 7.4 percentage points on a YoY basis, and adjusted EBITDA reaching RMB69.7 million during the period, increasing by 39.7% compared with the second half of 2021."We firmly believe that fast-tracking development in the local lifestyle market brings significant real and quantifiable value to consumers and merchants, because consumers can find intriguing experiences and receive actual discount by using our services, and merchants can boost their revenue and name recognition through our concentrated traffic during a short timeframe. The in-store e-commerce business has experienced strong growth in GMV, with MAU exceeding 19.0 million during 1H 2022, coupled with our effective operations optimization, we have significantly narrowed its loss. Going forward, we will continue to focus on creating user value, driving technology innovation, and taking more social responsibility."Also, with confidence in Yeahka's fundamentals and future strategies, we have purchased a total of 25,533,600 shares of the Company through the restricted share unit scheme, accounting for 5.65% of total shares outstanding. Moreover, on 30 August 2022, we announced an additional US$70 million share purchase scheme, reflecting our continued confidence in Yeahka's growth potential."OutlookOn one-stop payment services, Yeahka will continue to strengthen its sales network, particularly Open-API SaaS partnerships and bank partnerships. Yeahka will also look to embrace new payment standards such as DC/EP. On in-store e-commerce services, Yeahka will put utmost emphasis on improving user experience and focus on narrowing loss, as it is constantly optimizing its cost structure and operating efficiencies. Based on the strong results in the past few months, Yeahka is confident that it will continue to realize tremendous growth in GMV and increase market share. On merchant solutions, leveraging its strong payment merchant network, Yeahka will continue to empower merchants on optimizing digitalized operations and enhancing efficiency. Yeahka has raised US$70 million in July 2022 to strengthen its offshore balance sheet, and will explore overseas opportunities as cross-border travel gradually become available in China.Overall, empowering the real economy and creating values for merchants and consumers has always been Yeahka's core values since its inception in 2011. As Yeahka enters the second half of 2022, the Company may still face challenges from pandemic-driven weakened consumption environment. However, as it has demonstrated with its operating results in 1H 2022, Yeahka will continue to navigate through difficult times, capitalize on the data and traffic in its ecosystem and achieve healthy growth. Yeahka will continue to invest in research and development, enrich its product mix, enhance user experience, increase diversified revenue streams, extend business boundaries, and create sustainable value for shareholders, employees, and society.About YEAHKA LIMITED (Stock Code: 9923.HK)Yeahka is a leading payment-based technology platform dedicated to creating value for merchants and consumers. Our goal is to build an independent and scalable commercial digitalized ecosystem to enable seamless, convenient, and reliable payment services to merchants and consumers, and to further expand into serving merchants and consumers with our diversified product portfolio, which now includes (i) in-store e-commerce services, providing consumers with local lifestyle services of great value, and (ii) merchant solutions, enabling merchants to better manage and drive business growth.Investor and media enquiry:Yeahka LimitedIR teamEmail: ir@yeahka.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Far East Horizon Announces 2022 Interim Results

HONG KONG, Aug 29, 2022 - (ACN Newswire via SEAPRWire.com) - Far East Horizon Limited (Stock Code: 03360.HK), a leading financial services and industrial group in China, announced its interim results for the six months ended 30 June 2022.Financial ReviewIn the first half of 2022, the international and domestic environment was complex and volatile, with increasing risks and challenges. Although the environment was posing new challenges to China's stable economic growth, the economy generally demonstrated a steady recovery. In reliance upon China's real economy, the Group continued to adhere to the operational philosophy of "finance + industry", and achieved stable growth in overall results in spite of the complicated and ever changing macro environment.During the Review Period, the Group realized revenue of RMB17.72 billion, representing an increase of 9.46% year-on-year ("YoY"). Among which, the financial and advisory segment remained stable overall with a slight increase, accounting for 65.17% of the total income (before taxes and surcharges). Structurally, financial services maintained growth, while advisory services recorded decline. The industrial operation segment continued to record substantial growth with an increase of 21.13% YoY, accounting for over 30% of the total income (before taxes and surcharges). The profit attributable to holders of ordinary shares of the Company during the Review Period amounted to RMB2,842 million, representing an increase of 10.47% YoY, basic earnings per share reached RMB0.68, together with the return on average equity (ROE) of 13.58%, demonstrating a steady growth momentum.Financial Business Developed Steadily with Significant Growth in Industrial OperationIn the first half of 2022, with respect to market competition, focusing on market changes and customer needs, the Group continued to strengthen the practice of the concept of "model innovation", and accelerated its implementation at the level of financial services and industrial operations, so as to form differentiated advantages from strategy to tactics, thereby ensuring the healthy development of the Company in a highly uncertain environment.In terms of financial business, to address the changes in financial needs in the market, the Group took "urban upgrading and industrial private bank" as its core strategy and simultaneously promoted the strategy in four aspects, namely the industry, customer base, regions and products. At the same time, the Group continuously strengthened the operational efficiency and service coordination of inclusive finance, overseas business, PPP investment, non-performing asset management and other businesses to ensure high-quality and stable development. During the Review Period, the income (before taxes and surcharges) of the financial and advisory segment was RMB11.60 billion, representing an increase of 4.17% YoY; Income derived from financial services increased by 12.39% YoY. In particular, interest income contribution from inclusive finance, commercial factoring, PPP investment, overseas business, asset business and other new business directions amounted to RMB1,187 million, representing an increase of 35.91% YoY. Income derived from advisory services decreased by 39.23% YoY mainly due to the active adjustment and continuous optimization of the Group's service structure in response to customers' needs after changes in the external operating environment.During the Review Period, the overall asset quality of the Group remained safe and under control. The non-performing asset ratio remained at a low level of 1.06% as at 30 June 2022, which remained the same as at the end of last year.In terms of industrial operation, the Group continued to stay close to the local markets, innovated service models, strengthened operational efficiency, emphasized management effectiveness, and highlighted differentiated competitive advantages. The income of the industrial operation segment sustained continuous growth. The industrial operation segment, which comprises of Horizon Construction Development, Horizon Healthcare and others, realized a total income of RMB6,198 million, representing an increase of 21.13% YoY. Income of the industrial operation segment increased to account for 34.83% of the total income.In particular, as a leading equipment operation service provider in China, Horizon Construction Development actively expanded its business size and consolidated its competitive advantages. Horizon Construction Development realized an income of RMB3,565 million during the Review Period, representing an increase of 46.73% YoY. As a large medical group funded by social capital in China, Horizon Healthcare has been actively responding to the country's call to encourage the communities to establish hospitals and expand the supply of quality medical services, continuing its focus on areas with scarce medical resources, and building a hospital network with unique Far East characteristics. During the Review Period, Horizon Healthcare realized an income of RMB2,067 million, representing an increase of 4.05% YoY.In the first half of 2022, in the face of the complex and difficult external environment, the Group adhered to its original aspiration and followed its development vision of "vigorously building excellent enterprises", placed more emphasis on the persistence and effectiveness of value creation, and continuously created incremental value for shareholders, customers, partners and employees. In the second half of the year, the Group will reinforce its strategic focus and operational efficiency, focus closely on the real economy, use finance as the major means to provide service, enrich service forms, enhance service capabilities, strengthen strategic synergies, and connect domestic and overseas markets, so as to lay a solid foundation for the Company's sustainable development.About Far East Horizon LimitedFar East Horizon Limited is one of China's leading innovative financial companies focusing on the Chinese fundamental industries and leveraging the business model of integrating finance and industry to serve enterprises of greatest vitality with the support of the fast-growing and enormous economy in China. Based on its operational philosophy of "finance + industry", Far East Horizon endeavours to realize its vision of "Integrating global resources and promoting China's industries" by making innovations in products and services to provide our customers with tailor-made integrated operations services. Over the past more than 10 years, the Group has been leading the development of the industry, and has been listed among the Fortune China 500 and Forbes Global 2000.Over the past two decades, the Group has evolved from a single financial service company into an integrated service provider with a global vision centered on China so as to facilitate national economic and sustainable social development. With the creative integration of industrial services and financial capital and with unique advantages in the organization of resources and value added services, we provide integrated finance, investment, trade, advisory and engineering services in healthcare, cultural & tourism, engineering construction, machinery, chemical & medicine, electronic information, public consuming, transportation & logistics, urban public utility as well as other fundamental sectors.The Group, headquartered in Hong Kong, has business operations centers in Shanghai and Tianjin, and has offices in major cities throughout China such as Beijing, Shenyang, Ji'nan, Zhengzhou, Wuhan, Chengdu, Chongqing, Changsha, Shenzhen, Xi'an, Harbin, Xiamen, Kunming, Hefei, Nanning and Urumqi, forming a client service network that covers the national market. The Group has been successfully operating its multiple specialized business platforms in China and abroad in financial services, industrial investment, hospital investment and operations, equipment operation services, exquisite education, trade brokerage, management consulting, engineering services, etc.The Company was officially listed on the Main Board of The Stock Exchange of Hong Kong Limited on 30 March 2011. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Analogue Achieves Record-High Contracts-in-Hand of HK$12.9 Billion in First Half of 2022, Consolidated Net Profit at HK$119.2 Million ACN Newswire

Analogue Achieves Record-High Contracts-in-Hand of HK$12.9 Billion in First Half of 2022, Consolidated Net Profit at HK$119.2 Million

HONG KONG, Aug 26, 2022 - (ACN Newswire via SEAPRWire.com) - Analogue Holdings Limited ("Analogue" or the "Company", together with its subsidiaries, collectively the "Group") (stock code: 1977), a leading electrical and mechanical ("E&M") engineering service provider in Hong Kong, today announced its interim results for the six months ended 30 June 2022 ("the Period" or "1H2022"), having achieved revenue growth and record-high contracts-in-hand amid market challenges. The Group's total revenue grew by 29.5% year-on-year to HK$3,022 million, mainly attributable to the increase in revenue from the Building Services segment. Gross profit also soared by 41.6% year-on-year to HK$457.6 million, thanks to the higher revenue and higher margins from the Building Services segment. The gross profit margin improved to 15.1%. Consolidated net profit would have increased by 5.9% year-on-year to HK$119.2 million before provision for potential litigation liabilities, with the profit attributed to owners of the Company reported at HK$59.2 million. The Board has proposed an interim dividend of HK4.27 cents per share, representing a dividend payout ratio of 50%.Highlights-- Record-high contracts-in-hand amounted to HK$12.9 billion, up 8.8% year-on-year-- Total revenue increased by 29.5% to HK$3,022 million -- The consolidated net profit at HK$119.2 million before provision for potential litigation liabilities. The profit attributed to owners of the Company reported at HK$59.2 million-- Gross profit margin rose from 13.8% to 15.1% year-on-year-- Healthy cash position with cash balance amounting to HK$1,073.7 million-- High dividend payout ratio maintained at 50%The value of contracts awarded to the Group during the Period grew significantly by 96.6% year-on-year, while its contracts-in-hand also reached a record high of HK$12,919 million as at 30 June 2022, providing a strong foundation for the core business' further expansion. The Group's tendering activities remained active during the Period, with 675 tenders or quotations valued at over HK$1 million each. Dr. Otto Poon Lok-to, Chairman of Analogue Holdings Limited, said, "Despite the many challenges encountered, I believe we have made a good start in 2022, maintaining growth in business scale and new contract wins, as well as achieving record-high contracts-in-hand. Over the course of the Group's 45-year journey, we are honoured to have fortified our leading position in the industry, kept abreast of developments over the years and continued to adhere to and reinforce the best business practices. Leveraging our 'New Technology, New Market, New Business Model' master plan, we are well positioned to enjoy a more advantageous and distinguished position in the industry and to sustain the long-term growth of our business."As the Group's major growth driver, Building Services segment's revenue increased by 43.7% to HK$2,036 million. Its recurring revenue stream increased with new maintenance contracts worth more than HK$127 million secured. Contracts-in-hand of this segment reached HK$6,391 million, in which HK$3,534 million were newly secured projects, including infrastructure, shopping malls, office buildings, data centres, residential developments and hotels in Hong Kong, Macau as well as the Mainland China. Moreover, in view of the urgently-needed capacity of mortuaries due to the increase in mortality rate during the COVID wave in 1H2022, the Group proactively adopted its proprietary ATAL Building Services Prefabrication and Modularisation Construction Technology ("ABSPM") coupled with digitalisation technologies for improved quality, safety, cost and project management of a public mortuary project, and successfully completed it by mobilising teams of workers on very short notice. Leveraging its strong track record, the Group is well placed to seize the upcoming business opportunities generated from the rapid development of data centres, as well as the expansions of railway lines and hospitals in Hong Kong. As of 30 June 2022, Environmental Engineering segment's contracts-in-hand amounted to HK$4,953 million, including five new contracts that underscore our expertise in project management services, as well as operation and maintenance contracts for electrical and mechanical works for water, wastewater and solid waste management. The Group will continue to implement innovative approaches for reinforcement, protection, operation and maintenance of treatment plants to extend their working life and ensure they are operated and maintained at optimal capacity to serve the Hong Kong community. On the research and development (R&D) front, the Group's proprietary "Digital Twin technology" was further advanced to monitor the influent quality of incoming sewage at a sewage plant in a more efficient manner. Tendering activities outside Hong Kong and the Mainland China included water treatment works at Kaliwa and Wawa, both in the Rizal Province of the Philippines.Information, Communications and Building Technologies ("ICBT") segment's contracts-in-hand rose by 13.0% year-on-year to HK$1,059 million. To support the development of Hong Kong's "Smart City" and "Smart Economy" visions, the Group has spared no effort in adopting green and intelligent building solutions which integrate a wide range of information and communications technologies with AI, robotic solutions, energy and management technologies. As a result of its strong R&D capabilities, the Group's AI Energy Management Platform, Internet of Things ("IoT") applications, Video Analytics technology, and "walkable" Photovoltaic ("PV") have been chosen for a world-class 36-storey smart office and commercial building project in Central, Hong Kong's prestigious CBD. Going forward, the Group will continue to deploy digital technologies to its maintenance service capabilities and invest to drive digital transformation across smart building technologies. The Lifts and Escalators segment's contracts-in-hand amounted to HK$516 million as of 30 June 2022, with the majority of profit contributed by maintenance contracts. In the overseas markets, our Anlev Elevator Group ("Anlev") secured strategic orders for mass transportation in Brazil and the hotel industry in Mexico. It is also finalising orders for an iconic and prestigious residential project in the United Kingdom through its wholly owned subsidiary Anlev (UK) Limited. To further expand its global footprint, the Group will seek new distributors in the United States, Europe and Southeast Asia. In parallel, the Group is completing a RMB60 million expansion of its Nanjing factory facilities to increase production capacity for lifts and escalators to meet the anticipated demand and growth of the global business.In 2022, the Hong Kong Government has budgeted a steady increase of spending on public capital works projects of at least HK$100 billion in each of the coming years. Additionally, the annual construction output is estimated to reach HK$300 billion, which will include a variety of public and private housing, commercial development and infrastructure projects in new towns. An expenditure of HK$200 billion is also expected as part of the 10-year Hospital Development Plan with a further HK$300 billion investment in the second 10-year Hospital Development Plan. All of these plans, together with Hong Kong's Smart City and Smart Economy visions, the thriving development of data centres and expansion projects of mass transit railway in Tung Chung, Hung Shui Kiu, Tuen Mun and Kwu Tung present tremendous opportunities. The Group is well-positioned to capitalise on these many growth opportunities and add value to customers by leveraging its capacity for innovation, digital technology, and passion to deliver results more effectively, efficiently and sustainably.Leveraging its successful experience in equity partnership with Transel Elevator & Electric Inc. ("TEI"), one of the largest independent lifts and escalators companies in New York, and the establishment of Anlev subsidiaries in the United Kingdom, the Group will seek synergistic business partners where appropriate to expand its footprint, create new business opportunities and build new revenue streams. Dr Poon concluded, "Being buoyed by the 'can-do spirit' of the new Hong Kong SAR Administration, we will grasp the tremendous opportunities arising from the increasing infrastructure development moving onward, leveraging our depth of expertise and experience in the industry. In addition to the local market, we are also cautiously optimistic about the development opportunities in various overseas countries that are now proceeding with major infrastructure developments, which have added motivation to our global expansion efforts. With our motto 'We Commit, We Perform, We Deliver', we have confidence that Analogue will witness further business growth in the years to come."For more details of the 2022 Interim Results, please refer to the announcement that has been filed with The Stock Exchange of Hong Kong Limited.https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0826/2022082600423.pdfAbout Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading electrical and mechanical ("E&M") engineering service provider headquartered in Hong Kong, with operations in Macau, Mainland China, the United States and the United Kingdom. Serving a wide spectrum of customers from public and private sectors, the Group provides multi-disciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies ("ICBT") and Lifts & Escalators. The Group also manufactures and sells Anlev lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. ("TEI"), one of the largest independent lifts and escalators companies in New York, the United States. The Group's associate partner, Nanjing Canatal Data Centre Environmental Tech Company Limited (603912.SS), is specialised in manufacturing of precision air conditioners. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Fujitsu and Tsuda University launch joint research on social design to realize sustainable, flexible community health care amidst aging society JCN Newswire

Fujitsu and Tsuda University launch joint research on social design to realize sustainable, flexible community health care amidst aging society

TOKYO, Aug 25, 2022 - (JCN Newswire via SEAPRWire.com) - Fujitsu Limited and Tsuda University today announced the launch of a social design joint research project to realize sustainable and flexible community health care services in Japan. The project aims to realize a framework to provide patients with high-quality medical and health services even with limited social resources by leveraging converging technologies: advanced technologies that combine computer sciences including AI with the humanities and social sciences such as empirical economics. The project is scheduled to commence on August 25, 2022.Image of the joint researchWithin this project, Fujitsu and Tsuda University will digitize so-called "care pathways," the flow of medical and health services that patients receive, including disease prevention, treatment, and prognosis. Leveraging Fujitsu's AI technology to predict patients' conditions on the care pathway from medical and health data (1) and Tsuda University's findings from empirical economics (2), the two parties will analyze patients' care pathways and identify bottlenecks in existing regional healthcare systems to ultimately offer patients more efficient and high-quality health services. With the cooperation of medical institutions and local governments in Japan, the two parties aim to establish a methodology to propose improvements to patients, local governments and service providers, and to build consensus for the practical implementation of these proposals in society.By the end of FY 2024, Fujitsu aims to connect people with medical institutions, companies, and governments, and apply the sustainable and highly flexible care pathway design technology developed in this joint research to help realize a more consumer-centric industry and society. Fujitsu will further conduct field trials with the goal of applying the newly developed service to a wide range of global medical and health service providers in Japan and beyond. Fujitsu will continue to promote "Healthy Living," one of its key focus areas under its global business brand Fujitsu Uvance, to create a world that enriches the life experience of everyone.An aging society: growing need for transparent, patient-centered innovationThe rapid aging of society represents an ongoing, urgent social issue in many parts of the industrialized world. In Japan, the ratio of the population aged 65 and over has reached 28.6% in recent years (3). As the aging of society continues to increase in many countries, building a sustainable service provision system that can maintain the quality of medical care and nursing care by efficiently using limited resources is developing into a major societal issue confronting the world.However, medical and health services, including those relating to disease prevention, treatment, and prognosis, are currently provided as separate services, and comprehensive coordination of these services based on a patient's condition and situation is not yet possible. Due to this lack of coordination, patients, for example, that are transferred between different hospitals, tend to feel insecure as they cannot overview their further treatment. Yet, attempts to improve the quality of medical and health services prove to be problematic, as they require a large amount of social resources and improvements often even lead to a lower efficiency in the provision of services.Within this project, the two parties will combine Fujitsu's digital technologies including an AI-based technology to predict patient conditions and a matching technology to derive fair assignments with Tsuda University's research findings from empirical economics perspectives, such as health innovation through hospital downsizing (reduction of hospital beds) and urban space realignment (4).About the joint research1. Period:August 25, 2022 - March 31, 2023 (scheduled to continue after April 1, 2023)2. Research Overview:Fujitsu and Tsuda University will conduct region-wide analysis of patients' "care pathways" (the flow of medical and health services) based on delivery systems and procedures planned by medical institutions and local governments, in combination with patients' actual medical and health data (receipt information etc.) to identify bottlenecks in current healthcare systems such as regional disparities in delivery systems and prolonged hospitalization. To identify bottlenecks, Tsuda University will analyze the problem areas by combining its accumulated knowledge in empirical economics with Fujitsu's AI technology to predict patients' conditions on the care pathway from medical and health data. To reduce the identified bottlenecks, Fujitsu and Tsuda University aim to improve both the quality of services to patients and the efficiency of service provision throughout the region. To this end, the two parties will develop a care pathway design technology to improve plans for systems and procedures for providing medical and health services that can resolve issues from the perspective of patients, local governments, and service providers in the region.To realize practical application of improvement plans for medical and health service provision systems and procedures, Fujitsu and Tsuda University will cooperate with medical institutions and local governments to establish a methodology for consensus building through solution proposals based on empirical economics.3. Roles and responsibilities:Fujitsu- Centralized visualization of patients' individual care pathways across the region and identification of bottlenecks- Development of technology to design improvement plans for care pathways based on medical and health dataTsuda University- Visualization of diseases and medical indicators such as physical functions and cost-effectiveness based on medical and health data- Proposal of policies related to regional healthcare delivery systems and setting up of forums for discussion toward consensus building- Analysis of methodologies for a balanced downsizing of healthcare facilities (reduction of hospital beds) and improvement of therapeutic efficacyFuture PlansAs part of this joint research, Fujitsu and Tsuda University will conduct verification tests using medical and health data in cooperation with Yamagata University (5) and other organizations, including hospitalization records and outpatient medical records in Japan's Yamagata Prefecture, which is promoting the establishment of a community-based healthcare system. Fujitsu and Tsuda University will apply the results of their joint research to communal heath institutes in the Yamagata Prefecture and other regions to verify the effectiveness of their newly developed system.(1) Medical and health data: Data from the DPC system ("Diagnosis Procedure Combination data", information collected and managed by the Japanese Ministry of Health, Labour and Welfare pursuant to the provisions of Paragraph 5 (iii) of the "Calculation method for the amount of expenses required for medical treatment in wards of hospitals designated by the Japanese Minister of Health, Labour and Welfare") and the KDB system ("Kokuho Database" - "The National Health Insurance Database of Japan") is used to create statistical information from benefit information (medical checkups, medical care, and nursing care) managed by the Japan Health Insurance Association through various operations, as well as data on patient health entrusted by insurers. Both data types are encrypted so that patients cannot be identified.(2) Empirical economics: An approach to economic methodology that considers empirical analysis based on economic theory.(3) The ratio of the population aged 65 and over has reached 28.6% in recent years: Statistics Bureau of Japan, News Bulletin December 28, 2021(4) Health innovation through hospital downsizing (reduction of hospital beds) and urban space realignment: By reducing hospital beds, the number of personnel will be increased to provide more intensive services to each patient. The goal is to improve health by providing comprehensive services to patients in the non-occupied space of the hospital (Research representative: Yukiko Ito, Professor, Department of Policy Studies, Tsuda University). https://www.jst.go.jp/ristex/stipolicy/project/project30.html (in Japanese)(5) Yamagata University:Main campus: Yamagata City, Yamagata Prefecture; President: Hidetoshi Tamate.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.About Tsuda UniversityTsuda University is a private institution of higher education for women, with a history of more than 120 years since its founding. It has two colleges and the Graduate School, which are now located on two campuses in Tokyo. Since its foundation, Tsuda University has cultivated women who demonstrate leadership with their practical expertise and analytical insights grounded in solid and wide-ranging knowledge. Tsuda University has also earned an excellent reputation for producing distinguished alumnae who have contributed to society locally as well as internationally in various fields. Find out more: https://www.tsuda.ac.jp/en/. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
REDSUN SERVICES’s 2022 Interim Profit Attributable to Equity Shareholders Increases 15.8% to RMB69.3 million ACN Newswire

REDSUN SERVICES’s 2022 Interim Profit Attributable to Equity Shareholders Increases 15.8% to RMB69.3 million

HONG KONG, Aug 23, 2022 - (ACN Newswire via SEAPRWire.com) - Redsun Services Group Limited ("Redsun Services" or the "Group"), a fast-growing comprehensive community services provider with a strong presence in the Yangtze River Delta region, has announced its interim results for the period ended 30 June 2022. The Group reported collaborative development in its three business lines of property management services, value-added services for non-property owners and community value-added services. The Group's external expansion grew rapidly while profitability remained stable. FY2022 Interim Results Highlights:-- The Group's revenue was RMB553.9 million, representing an increase of 4.7% compared with the same period last year.-- Revenue from property management services was RMB404.2 million, representing an increase of 15.3% as compared with the corresponding period last year and accounting for 73.0% of the total revenue. -- Profitability remained stable with a gross profit margin of 27.2%, while profit attributable to equity shareholders was RMB69.3 million, an increase of 15.8%.-- As at 30 June 2022, the Group had a total of 376 contracted projects, with contracted GFA increasing approximately 14.7% to approximately 56.9 million sq.m., of which there were 307 projects under management, with GFA of approximately 44.9 million sq.m., representing an increase of approximately 30.6%.Three-pronged business model with collaborative developmentThe Group recorded total revenue of RMB553.9 million, representing an increase of 4.7% compared to the same period last year. Revenue from property management services increased by 15.3%, accounting for 73.0% of the total revenue. Overall gross profit reached RMB150.8 million with a gross profit margin of 27.2%. Profit attributable to equity shareholders was RMB69.3 million, an increase of 15.8% as compared with the same period last year. The net profit margin reached 13.3%. As at 30 June 2022, the Group provided property management services and value-added services in 62 cities in China, with 376 contracted projects and contracted GFA of approximately 56.9 million sq.m., representing an increase of approximately 14.7% when compared with 30 June 2021, of which the GFA under management was approximately 44.9 million sq.m., an increase of approximately 30.6% as compared with the same period last year, serving as proof that the Group's management scale has reached a new level. During the period, the Group's GFA under management from third-party developers increased to 63.0%, representing an increase of 3.6 percentage points as compared with the same period of last year.External expansion continues at rapid pace, demonstrates tending capabilitiesDuring the review period, the Group gave play to the advantage of Nanjing "home city" to expand the development tracks of urban services. The Group continued to develop service projects in Taishan Street, Jiangbei New District, Nanjing and Xigang Street, Qixia District, Nanjing. Continuously penetrating the sector of logistics management services for expressways, the Group cooperated with Hubei United Transportation Investment Co., Ltd. to provide logistics services such as cleaning environment, order maintenance and engineering maintenance for its 12 stations including Wuhan Heping-Zuoling Expressway. Leveraging its reputation and courteous and customized professional services provided during the epidemic in Shanghai, the Group successfully obtained the Shanghai Henlius Industrial Park Project through market-oriented bidding expansion to provide property management services for large-scale pharmaceutical enterprisesAdhering to integrity and innovation to promote high-quality developmentIn 2022, the Group insisted to think everything from the customers' perspective and explore future demand of customers. It has upgraded the Redsun Mode 2.0 to establish "five good services" with basic service quality as the focus, which further solidified our basic service quality. The "Redsun Housekeeper" service products under this model have now been launched in full swing in the Group. The Group's organizational efficiency has been continuously improved and its efforts to enhance quality and efficacy have achieved a satisfactory outcome.In addition, focusing on customers' needs and advantageous areas of property management enterprises, the Group constantly diversified the community living service ecosystem and built up professional service capabilities. It integrated premium supplier resources and continuously penetrated deeply into various segments of business including Redsun community resources value-added services, Redsun Property Decoration Centre, and Hong Life Rental & Sales Centre. While extending the professional values of the Group, Redsun Services has also upgraded the value of assets and community spaces for property owners. At the same time, in compliance with the boost of "intelligent empowerment", the Group actively promoted digital construction and carried out smart upgrades, where it continuously iterated and upgraded the "Hongtu panoramic smart data platform", "management and control platform of all-dimensional plan", "Hongzhi Cloud Monitor" and "online management and control platform of investment and development", for the purpose of enhancing management efficiency while controlling operation costs.In the future, Redsun Services will continue to adhere to the high-quality and steady development strategies. With the support of comprehensive improvement in the organizational and cultural ability of talents, the Group will enhance its professional, standardized, high-quality, systematic service operational capabilities as well as service design and innovative capabilities, so that it can create excellent comprehensive servicing capabilities in the all-round development of "space + scenario" operational capabilities, and take this as the basis for building its healthy and sustainable development capabilities to realize the long-term value of the Group.About Redsun Services Group LimitedEstablished in Nanjing in 2003, Redsun Services Group Limited is a fast-growing comprehensive community service provider focusing on the Yangtze River Delta. With a vision of "making lives warmer," the Group has provided and endeavors to continue to "provide customers with high-quality services with sincerity" to better serve its customers. The Group has established the regional leading position in the property management market of Jiangsu province and is well-recognized nationwide. The Group was recognized as one of the Top 100 Property Management Companies by CIA for four consecutive years since 2017 and ranked 18th among the 2022 Top 100 Property Management Companies in terms of overall strength. In December 2020, the Group was included by FTSE Russell in the FTSE Global Micro-Cap Index. In 2021, the Group was selected as a constituent of the Hang Seng Property Service and Management Index. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
IVD Medical Announces 2022 Interim Results ACN Newswire

IVD Medical Announces 2022 Interim Results

HONG KONG, Aug 22, 2022 - (ACN Newswire via SEAPRWire.com) - IVD Medical Holding Limited ("IVD Medical" or the "Group"), a leading distributor of In Vitro Diagnostic ("IVD(1)") products in the PRC, has announced its interim results for the six months ended 30 June 2022 ("Period"). During the Period, although hospitals were closed and other quarantine and social distancing measures were put in place in mainland China due to the COVID-19 pandemic, which resulted in a temporary decrease in end customers' demand for IVD product. With the help of its competitive and diverse product portfolio, extensive distribution network and growing maintenance services business, the Group still recorded revenue of RMB1,176,557,000 (six months ended 30 June 2021: RMB1,186,791,000), a similar level to that in the same period last year. Gross profit increased by 11% year-on-year to RMB266,423,000 and gross profit margin was up 2.4 percentage points year-on-year to 22.6%. The increases were mainly attributable to the decrease in purchase price of IVD analysers and the increase in maintenance services revenue with relatively stable maintenance cost. Driven by rising profit margin, the Group's adjusted profit for the period amounted to RMB96,773,000, 6.7% more year-on-year. The Board resolved to declare the payment of an interim dividend of HK2.729 cents per share for the six months ended 30 June 2022. Mr. Ho Kuk Sing, Chairman of IVD Medical, said, "In 2022, although the business environment of the medical industry has been tough under the pandemic, we have worked hard to overcome challenges and optimize our business operations. For distribution business, we signed a five-year exclusive distribution agreement with Sysmex in April this year. We have expanded our distribution network and hospital coverage to consolidate our position in the industry. Furthermore, our maintenance services business has been developing steadily with the notable growth in revenue, gross profit and gross profit margin. Looking ahead, we are prepared to capture potential growth opportunities in the industry and committed to bring better and long-term returns to shareholders."Business ReviewThe Group is a leading distributor of IVD products in the People's Republic of China ("PRC"). It has also engaged in research, development, manufacturing and sales of its self-branded IVD products.Distribution BusinessThe distribution of IVD products forms the cornerstone of the Group's business. It primarily involves the trading of IVD analysers, reagents and other consumables to customers such as distributors, hospitals and healthcare institutions and logistics providers. During the Period, revenue from this segment was RMB1,097,468,000, with gross profit up 3.1% to RMB216,907,000.Through years of operation, the Group has established an expansive distribution network across 29 provinces, municipalities and autonomous regions in the PRC with an extensive hospital coverage. As of 30 June 2022, the Group has 204 direct customers, including hospitals and healthcare institutions, and 908 distributors in its established distribution network. The Group distributes IVD products through its wholly-owned subsidiary Vastec Medical Limited ("Vastec"). Vastec has been the sole nationwide distributor of Sysmex haemostasis products with exclusive distribution rights in the PRC since 1997, and also procures a diversified portfolio of IVD products from other leading international brands for distribution in the PRC. On 1 April 2022, Vastec signed a five-year distribution agreement of Sysmex haemostasis products with exclusive distribution rights which is valid till 31 March 2027. The agreement has helped to strengthen the long-term and quality cooperation between Vastec and Sysmex. Moreover, the Group has provided four Thrombotic Markers(2) products manufactured by Sysmex to the market. These products adopt highly sensitive chemiluminescence technology, which may facilitate early diagnosis of thrombosis and fibrinolysis. The Group also provides solution services to clinical laboratories of hospitals, as such, it has enabled the Group to establish and maintain direct relationships with local medical practitioners so as to keep the Group close to the frontline of the medical practice and the demand of IVD products. In the first half of 2022, the Group provided solution services to eight Class III hospitals in the PRC.Maintenance ServicesThe Group provides maintenance services to end customers of Sysmex' haemostasis analysers. In 2017, Vastec entered into a maintenance services agreement with Sysmex to provide maintenance services to haemostasis analysers procured by its end customers. The maintenance services provided by Vastec generally include maintenance and repair services, installation services and end customer trainings. And, it primarily provides its maintenance services to hospitals and healthcare institutions. During the Reporting Period, the maintenance services business has been sustainably and steadily developing, with revenue amounted to RMB77,286,000, up by 27.8% against the same period last year. Gross profit of this segment increased by 70.2% to RMB48,388,000 and gross profit margin was up 15.6 percentage points to 62.6% for the period. Self-Branded Products BusinessThe Group has also engaged in the research and development, manufacturing and sales of IVD analysers and reagents under its own brand. The Group's self-branded IVD reagents were manufactured by Suzhou DiagVita Biotechnology Co., Ltd. and Bazoe Medical Co., Ltd., and the Group's IVD analysers were produced by its equipment manufacturers, IVD Medical Equipment (Shanghai) Ltd. and Langmai Biotechnology (Shandong) Co., Ltd. In addition, the Group distributes self-developed IVD products under its own brand which includes IVD analysers and reagents primarily under the IVD testing category of Point-of-care testing ("POCT"), mass spectrometry and microbiology.OutlookIn the future, the Group will continue to consolidate its leading position in the IVD industry in the PRC. To realise this goal, the Group aims to continuously expand its product portfolio by diversifying product categories, increasing brand coverage, and further expanding the breadth of its distribution network and hospital coverage. In this way, the Group will be able to capitalise on the high growth potential in the IVD market.Furthermore, the Group will continue to develop its distribution business by enhancing its capacity in providing solution services. By being the general supplier of the clinical laboratory department in such hospitals, the Group participates in the design of laboratory layout, provides centralised procurement of IVD products, conducts real-time inventory monitoring and provides other after-sale services to clinical laboratories. It also plans to hire more sales personnel to promote and market its solution services and to stock sufficient IVD products of various brands to strengthen its advantages in centralized procurement. To enhance brand awareness, it will continuously participate in national and local IVD symposiums, as well as academic conferences. In addition, the Group believes that strong research and development ("R&D") capabilities are critical to securing its future development and sustainable growth. It will therefore invest more resources to further improve its R&D capabilities by acquiring equipment, instruments and hiring experts in the relevant fields. The Group will also engage in research projects to further develop self-branded IVD products that holding promising market potential. The Group is keen to further strengthen product quality management and optimize the performance and applicability of self-developed products to improve market competitiveness.Mr. Leung King Sun, Chief Operation Officer of the Group, said, "Given the growing medical expenses per capita and government support to the industry pursuing technological development, the Group remains optimistic about the development prospects of the medical market in the PRC, particularly the medical equipment market. Priding competitiveness, a diverse product portfolio, an expansive distribution network and extensive hospital coverage, we are confident of seizing every potential opportunity. Meanwhile, we will continue to strengthen solution services for hospitals and enhance R&D capabilities for our own brands, and ultimately consolidate our leading position in the industry."About IVD Medical Holding LimitedIVD Medical Holding Limited ("IVD Medical" or the "Group") is a leading distributor of IVD products in the PRC. Its key subsidiaries include Vastec Medical Limited, Dacheng Medical Equipments (Shanghai) Co., Ltd., IVD China Limited, Suzhou DiagVita Biotechnology Co., Ltd., Langmai Biotechnology (Shandong) Co., Ltd and Bazoe Medical Co., Ltd. The Group's distribution network covers 29 provinces, municipalities and autonomous regions across the PRC. It is the sole national distributor of Sysmex' haemostasis products in the PRC and provides maintenance services to its end customers. It also engages in the R&D, manufacturing and sales of self-branded IVD analysers and reagents and provides solution services to clinical laboratories of hospitals for centralised procurement.Notes:(1) IVD, "In Vitro Diagnostic", which encompasses tests done on samples such as blood or tissue taken from the human body(2) 4 Thrombotic Markers refer to: 1)TAT: Thrombin-antithrombin complex, 2)PIC: Plasmin - a2-plasmin inhibitor complex, 3)TM: Thrombomodulin, 4)t-PAI-C: Tissue plasminogen activator/plasminogen activator inhibitor-1 complex.Media Enquiries:Strategic Financial Relations LimitedHeidi So Tel: (852) 2114 4320 Email: heidi.so@sprg.com.hkYan Li Tel: (852) 2864 4826 Email: yan.li@sprg.com.hkCherry Chen Tel: (852) 2114 4309 Email: cherry.chen@sprg.com.hkFax: (852) 2527 1196 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY ACN Newswire

Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY

HONG KONG, Aug 19, 2022 - (ACN Newswire via SEAPRWire.com) - Shanghai Applied Protein Technology Co., Ltd. ("APTBIO"), a leading enterprise focused on mass spectrometry-based multi-omics applied to precision medicine, recently announced the completion of its Series B with hundreds of millions of CNY, which is led by Legend Capital. The proceeds from this round of financing will be used to accelerate the product R&D, market expansion, and data-driven precision medicine development and help APTBIO continue to develop in mass spectrometry multi-omics applications, innovative drug development, and preclinical research, making a forward-looking layout for the construction of precision medicine services driven by big data and AI. Founded in July 2004, APTBIO is one of the earliest biotechnology companies engaged in proteomics technical services and biopharmaceutical research and analysis services in China and participated in establishing China's biological mass spectrometry applications from scratch. With headquarter in Shanghai, APTBIO has a nationwide sales network and it has built innovative technology centers, data centers, and clinical testing centers in Shanghai, Yiwu, and Taizhou, with a total area of more than 20,000 square meters. Centering on the construction of the life and health industry chain, APTBIO has established four major technology platforms through technical cooperation and its innovation capabilities: a large-scale multi-omics platform, biopharmaceutical preclinical research and small-scale production platform, mass spectrometry clinical detection and companion diagnostic platform, and an AI and big data platform. By laying out the three business segments of technology services, biomedical CRO services, and mass spectrometry clinical testing services, APTBIO has built a business map around multi-omics and big data to provide a precise platform for the perfect transformation from basic research to clinical application. Ms. CHEN Wei, the founder of APTBIO, said: "I would like to take this opportunity to extend my sincere gratitude to our investors. This round of capital input fully validates the rapid development and future potential of APTBIO in mass spectrometry multi-omics-based precision medicine and pre-clinical CRO for drug R&D. With the completion of the new round of financing, we will further promote the local and global market layout, innovative biomedical business interaction, and data-driven precision medicine capacity, to contribute to the human health industry."Hank ZHOU, the co-chief investment officer of Legend Capital, said: "APTBIO is a leading enterprise in multi-omics R&D services in China, covering a wide range of areas such as technology services, biomedical R&D, precision medicine, and it provides integrated services for the transformation from basic research to clinical application. APTBIO has laid out cutting-edge technologies in various fields in advance, such as proteomics and metabolomics, and its high-quality R&D technical team has achieved breakthroughs in multiple research fields. We are honored to participate in the future development of APTBIO and are willing to work together with the company to establish APTBIO as a leader in the multi-omics R&D industry."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully ACN Newswire

Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully

HONG KONG, Aug 15, 2022 - (ACN Newswire via SEAPRWire.com) - On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange. R&G Pharmastudies publicly issued 15,000,000 shares at a price of RMB78.88 per share, and the total amount of funds raised is expected to be RMB1.18 billion.R&G PharmaStudies is a large-scale professional clinical trial outsourcing service supplier in China. It has established a complete set of pharmaceutical R&D outsourcing service systems covering the whole chain of clinical trials. R&G PharmaStudies provides integrated services throughout the entire process of clinical trials with its comprehensive drug R&D service system; the main services offered by the company cover clinical trial operation services, clinical trial site management services, biological sample testing services, data management, and statistical analysis services, clinical trial consulting services, clinical pharmacology services, etc. R&G PharmaStudies is committed to providing high-quality and efficient clinical research services in line with international standards. With a broad and high-quality customer base, it has provided professional services for about 750 Chinese and foreign pharmaceutical companies.Legend Capital invested in the Series A round of R&G PharmaStudies in the second half of 2017 and has kept on supporting the development of R&G PharmaStudies. Jafar Wang, the Co-Chief Investment Officer of Legend Capital, said, "Congratulations on the successful listing of R&G PharmaStudies! R&G PharmaStudies is a veteran of China's pharmaceutical clinical CRO industry and has long provided full-chain clinical CRO services for Chinese and foreign innovative pharmaceutical enterprises. The successful listing will be the starting point of the new long run of R&G PharmaStudies; with its global vision, well-known expert team, and high-quality service system, we are optimistic about the long-term development potential of R&G PharmaStudies, and look forward to the continuous growth of the company." Legend Capital has a systematic layout in CRO/CDMO. In addition to R&G PharmaStudies, Legend Capital has invested in plenty of other new-drug R&D CRO/CDMO companies, such as WuXi Apptec, WuXi Biologics, Pharmaron, Bellen, ClinChoice, SAFE Pharmaceutical, dMed Biopharmaceutical, XiHua Scientific, BirdoTech, Intellective Biologics, Biortus, and Simoon Record.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Yunkang Group Announces First Interim Results Since Listing, Net Profit Rises 50% to RMB234 Million ACN Newswire

Yunkang Group Announces First Interim Results Since Listing, Net Profit Rises 50% to RMB234 Million

HONG KONG, Aug 12, 2022 - (ACN Newswire via SEAPRWire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its first interim results for the six months ended 30 June 2022 (the "Reporting Period") since its listing. Driven by favorable government policies promoting healthcare in China, the three business segments of the Group, including Diagnostic Outsourcing Services, Diagnostic Testing Services for Medical Institution Alliances, and Diagnostic Testing Services for Non-Medical Institutions have achieved rapid growth, with total revenue increasing by 81.9 % year-on-year to RMB1,378.7 million. Gross profit also increased by 68.6% to RMB651.1 million compared with the same period last year, and net profit rose by 50.0% to RMB234.4 million, establishing a new high within the same responding period.Business ReviewHigh-quality growth of three business segments and continuous expansion of income and service levels During the Reporting Period, revenue from diagnostic outsourcing services rose 40.8% to RMB680.4 million, as products involved in such areas as tumors, infectious diseases, and blood diseases were maintaining steady growth. The Group offers diagnostic outsourcing services to hospitals, other medical institutions and public institutions, along with dozens of independent laboratories, including central laboratories, provincial comprehensive laboratories and regional rapid response laboratories nationwide, covering all major clinical testing technology platforms (such as immunoassay, mass spectrometry, PCR, high-throughput sequencing, liquid chip, ultrastructural pathology and digital pathology remote diagnosis) with more than 2,000 testing items and growing.Diagnostic testing services for medical institution alliances mainly assists leading hospitals in establishing on-site diagnosis centers covering four main types (i.e. pathology, infectious disease, genetic disease and routine diagnostic tests). Revenue from this segment rose by 166.2% to RMB650.7 million as at the Reporting Period. The increase was primarily due to the rise in number of on-site diagnostic centers - climbing from 275 as of the end of 2021 to 350 as of 30 June 2022, as well as further improvements in service capabilities and expansion in service scope of the on-site diagnostic centers after preliminary construction and operation, resulting in rapid growth in average revenue of the unit on-site diagnostic centers. As of 30 June 2022, the semi-annual average revenue of the on-site diagnostic centers was RMB1.9 million, compared with a full-year average revenue of RMB2.2 million in 2021. Diagnostic testing services for medical institution alliances represent a crucial operating segment of the Group, accounting for an increasing proportion of the Group's total revenue, rising from 32.2% of total revenue for the six months ended 30 June 2021 to 47.2% of total revenue for the six months ended 30 June 2022.Revenue generated from the diagnostic testing services for non-medical institutions segment increased by 56.7% to RMB47.6 million, primarily due to the significant increase in demand for COVID-19 tests by individual customers and non-medical institution customers amid the ongoing COVID-19 epidemic.Industry Potential The year 2022 has witnessed continuous and strengthening support on the policy front. The 2022 Government Work Report has drawn attention to the need to continue promoting hierarchical diagnosis and treatment and enhance the order of medical treatment; expedite the building of national and provincial regional medical centers; promote the extension of quality medical resources to cities and counties; and improve the capacity of primary disease prevention and treatment, so that people can have convenient access to better healthcare services. The Outline of the Fourteenth Five-Year Plan for the National Economic and Social Development and the Long-Range Objectives Through the Year 2035 of the People's Republic of China, released in March 2022, has pointed out that deepening reform of the medical and health system should be focused. It clearly specifies that reforms, such as establishing a modern hospital management system, expanding the capacity of quality medical resources and balancing regional presence should be expedited. The Outline also clearly states that the capacity of public health services should be significantly enhanced, and the quality of medical and health services should achieve continuous improvement by 2025. Furthermore, the capacity of primary medical and health services should be continuously improved, the comprehensive and full-cycle health services system should be gradually enhanced, and the landscape for hierarchical diagnosis and treatment should be gradually established.With a series of supportive policies and an array of subsequent national policies for promoting a stable economy set to successively come into effect, the healthcare service market in China will possess tremendous growth potential. According to a Frost & Sullivan Report, the total healthcare service market in China is expected to reach RMB7,519.6 billion by 2025, which represents a CAGR of 9.1% from 2020 to 2025. Benefiting from the introduction of supportive policies, and growing awareness of healthcare among the population, the size of the diagnostic testing services for medical institution alliances market in China is expected to grow to RMB5,903.4 million in 2025, from RMB2,200.9 million in 2020, representing a CAGR of 21.8%, hence will present tremendous business opportunities to the Group.Development StrategyContinue to expand and strengthen medical institution alliance networkOver the next few years, the Group will primarily focus on pathology, genetic and infectious disease laboratories for medical institution alliances and further improve their precision medicine capability, expanding and strengthening its medical institution alliance network. As at 30 June 2022, there were a total of 350 on-site diagnostic centers in hospitals. At the same time, the Group currently has nearly 90 ongoing projects involving on-site diagnostic centers with hospitals that have yet to commence operation. For certain hospitals that do not currently have diagnostic capacities, the Group intends to help them improve, manage, and operate such laboratories.The Group also plans to establish more sales and customer service representative offices to enable its sales and marketing and after-sales customer service personnel to more closely interact with customers and develop stronger and deeper business relationships. This would also facilitate better understanding of customers' needs and design and provide solutions to meet such needs, which in turn enable the Group to maintain its market position.Expand portfolio of diagnostic capabilitiesThe Group plans to expand its portfolio of diagnostic capabilities, in particular, for tumors, genetic diseases, infectious diseases and pharmacogenetics, hence, it will seek to further enhance its diagnostic testing technologies, upgrade its equipment and recruit more personnel as appropriate to support the expansion. As the Group expands its diagnostic capabilities, it also plans to market its services to more non-medical institution customers, such as corporations and government agencies, so as to enhance its ability to provide omni-scenario medical operation services for customers.The Group believes that precision medicine will be a growing trend in the healthcare industry as more and more patients seek customized medical solutions. Diagnostic testing is crucial to enhance precision medicine as accurate diagnostic testing will enable physicians to understand the characteristics of the patients to customize their treatment plan. Through continued expansion of its capabilities, the Group endeavors to work with hospitals to provide precision medicine solutions to patients.Continue to upgrade and enhance operational capabilitiesThe Group plans to strategically develop small-scale self-operated independent clinical laboratories (ICLs) in selected regions and areas of China, either near the Group's major customers or based on market needs, with the aim of digitalizing diagnostic testing and developing technical and operating systems to support its operations. In order to further enhance operational capabilities, the Group may consider acquiring or investing in companies that have synergistic businesses with it, such as upstream companies engaged in advanced diagnostic techniques, molecular biology, biotechnology and their clinical applications.Yunkang Group Limited (Stock Code: 2325)Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China, and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. So far, Yunkang has successfully provided professional services to 350 medical institution alliances. As of June 30, 2022, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Blockchain Development Company EvaCodes Raises $500,000 from Web3-oriented Hypra Fund SeaPRwire

Blockchain Development Company EvaCodes Raises $500,000 from Web3-oriented Hypra Fund

MIAMI, FL, July 27, 2022 – (SEAPRWire) – Blockchain development company EvaCodes raises a $500,000 round from the Web3-oriented hypra.fund. EvaCodes is a blockchain development company that provides Web3 development services for startups and enterprises interested in creating new products and services using blockchain. The company was founded in 2019 by two serial entrepreneurs and blockchain enthusiasts, Yehor Havrylenko and Vitalii Basiuk. Over the last year, EvaCodes has developed and launched more than 50 projects in the Web3 and blockchain industries. The agency provides a wide range of services. Among them are Cryptocurrency Development, Smart Contracts, Tokens and Tokenomics, dApps, DeFi and Fintech products, Digital Banking Products, NFT Marketplaces, and NFT Collections, Cryptocurrency Wallets and Exchanges, Metaverse development, EVM, L1/ L2, Play to Earn and other blockchain games, Real Estate Blockchain platforms, crypto trading bots and other products related to the blockchain industry. EvaCodes developed these projects using different blockchains: Ethereum/ Solidity, Solana/ Rust, Binance Smart Chain, Polygon, Near and other chains. The Web3-oriented hypra.fund was founded in March 2022 by Ukrainian investor Igor Pertsiya (ex-TAventures and CEX.io) and IT entrepreneur Dmitry Volkonsky (TRIONIKA). Besides investments, the fund helps companies get to the next level in operational processes, select an effective team, find the best tools for growth, and raise funding rounds. One of the features of the fund is that they build and develop projects with founders. “As a fund, we are creating our own ecosystem, where in addition to financial investments, consulting on scaling, and team development – we propose technical product development teams. EvaCodes has established itself in the market and has shown that its team has strong expertise in blockchain development and a vast number of successful cases under its belt. That is why we decided not only to invest but also to make EvaCodes a key technical element of the fund,” says Igor Pertsiya, partner and co-founder of hypra.fund. Yehor Havrylenko, CEO at EvaCodes says, “As the industry continues to evolve, the demand for quality Web3 products and skilled blockchain developers grows daily. We are grateful to the hypra.fund team for their trust, and hope that working together will bring fruitful results for both teams. We plan to use the money from the investment round to expand our business and attract new blockchain engineers and grow our client portfolio. Over the next 3-5 years, EvaCodes plans to launch its own products and startups using blockchain technology. One of those planned is Dating-to-Earn – an NFT Tinder. More announcements will be made soon.” About EvaCodes EvaCodes is a full-stack blockchain development agency focused on providing blockchain development services and building Web3 products. With its headquarters in the USA and development centers across Poland, Estonia, Ukraine, Armenia, and the USA, EvaCodes provides blockchain development services for their customers to create outstanding market-disrupting blockchain products. EvaCodes is a top-rated blockchain development agency reviewed by Clutch(5.0), GoodFirms (5.0), and Upwork (44 projects and 100% job success rate). Website: https://evacodes.com LinkedIn: https://www.linkedin.com/company/evacodes About hypra.fund Hypra.fund is a $25m Web3-oriented joint venture fund investing in and building projects with founders. Besides investments, the venture fund proposes ready-to-work blockchain development teams, helps companies reach a new level in operational processes, select an effective team, find the best tools for growth, and raise funding rounds. Website: https://hypra.fund Twitter: https://twitter.com/hypra_fund Media Contact Brand: EvaCodes Contact: Kseniya Prydybailo, PR Supervisor Email: blockchain@evacodes.com Website: https://blockchain.evacodes.com/ SOURCE: EvaCodes The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
EC Healthcare expects sales volume to increase no less than 17% Y-o-Y to no less than HK$860 million in the first quarter ACN Newswire

EC Healthcare expects sales volume to increase no less than 17% Y-o-Y to no less than HK$860 million in the first quarter

HONG KONG, Jul 25, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group expects the sales volume for the first quarter to increase no less than 17% Y-o-Y to no less than HK$860 million. To fulfill the strong demand for aesthetic medical and beauty and wellness services provided by the Group in Mainland China, in July 2022, the Group has opened two new service points in Shenzhen, with an aggregate newly leased gross floor area of approximately 12,400 square feet. The Group's total number of service points in Mainland China increased to 18.Benefiting from the strong demand on medical services provided by the Group and as the impact of the fifth wave pandemic outbreak gradually fades, the overall consumption sentiment in Hong Kong improves with a full-fledged retail sector recovery. The Board expects to record a no less than HK$860 million sales volume, representing a no less than 17% y-o-y increase and a no less than 80% increase as compared with the same period in 2020; the Group's sales volume of medical services is expected to achieve a no less than 29% y-o-y increase for the Quarter and a no less than 158% increase as compared with the same period in 2020; for sales volume in those clinics and services centers located in Mainland China, the Group is expected to record a minor y-o-y decrease for no more than 6% for the Quarter, and a no less than 29% increase as compared with the same period in 2020.Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "Looking ahead, the Group is confident about the business performance given the gradual fading impact of the pandemic, the community immunity increased and the health consciousness rising. The Group is expected to operate the business in a stable market environment and the demand for medical services will remain momentum. As the leading healthcare services provider in Hong Kong, the Group will keep developing businesses through organic growth as well as mergers and acquisitions, leveraging our investment in information technology, branding and service to enrich the closed-loop healthcare ecosystem and further consolidate the healthcare market."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine IpTel: (852) 2136 6952 / 2169 0467 / 3920 7649Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
EC Healthcare Provides Healthcare Services for Signature and Prestige Banking Customers of Hang Seng Bank ACN Newswire

EC Healthcare Provides Healthcare Services for Signature and Prestige Banking Customers of Hang Seng Bank

HONG KONG, Jul 18, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce the Group will provide diversified healthcare services for Signature and Prestige Banking customers of Hang Seng Bank via the brands under the Group, including New York Medical Group, Hair Forest, DR REBORN and ATO HAIR CLUB. As the leading healthcare services provider, EC Healthcare is committed to providing professional, premium and diversified medical healthcare services covering 29 medical disciplines and to bringing health, beauty and happiness to the world. EC Healthcare will safeguard the health of banking customers in line with the client-centric core value, and provide comprehensive healthcare, aesthetic and beauty and kids well-being and healthcare services for them and their children. The promotion period started from 1 July 2022 and will end till 30 June 2023.*Please refer to the [Terms and Conditions] on the Hang Seng website for detailed information.About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, focusing on preventive and precision medicine, the leverage investment in IT, brand, service and corporate culture aims build a diversified enclosed healthcare ecosystem, bringing health, beauty, and happiness to everyone. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic Premier Medical Centre, Specialist Central and New Medical Centre, a paediatric centre PrimeCare, a gynaecology specialist Zenith Medical Centre and Paternal Diagnosis Centre, PathLab Medical Laboratories, Ophthalmology Center Vivid Eye, and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Perfect Medical’s Major Shareholders Further Increase along with Company Buybacks, Strong Confidence in the Future Prospects

HONG KONG, Jul 8, 2022 - (ACN Newswire via SEAPRWire.com) - Perfect Medical Health Management Limited ("Perfect Medical" or the "Company", the "Group"; Stock code: 1830.HK), one of the largest medical groups in Hong Kong, together with its subsidiaries (collectively referred to as the "Group"), is pleased to announce that on the 4th and 5th July 2022, Dr. Au-Yeung Kong, the executive director, chairman and chief executive officer of the Group ("Dr. Au-Yeung") further purchase a total of 7,5000,000 shares of the Company, for an aggregate consideration of HK$30.675 million. Following the further purchase, Dr. Au-Yeung is interested in an aggregate of 909,287,383 shares and his equity stake increased from 72.92% to 73.33%. At the same time, on the 4th of July 2022, the Company repurchased 1,000,000 shares for an aggregate consideration of HK$3.978 million under the Repurchase Mandate, representing approximately 0.08% of the issued share capital. The Company announced its FY2021/22 annual results in late June. The Company achieved a historical high revenue of HK$1.35 billion, representing a growth of 23.9% despite the impact of the pandemic. The Company achieved a net profit of HK$305.2 million. If excluding the government subsidies in both years, the revised net profit for the Group increased by 29.8%. With a solid financial position, actively seeking mergers and acquisitions of medical projects and global expansion strategies, the Company will deliver sustainable growth in the long run. Dr. Au-Yeung, said that "the further purchase demonstrates the confidence about the future prospects of the Company and is optimistic about the Company's future development and may consider further increasing the shareholding in the Company when appropriate in the future. With the weakening of the impact of the pandemic, the Company is well-positioned to capitalize on the market opportunities and respond to the rebound of customers' demand in the post-pandemic era. In the future, the Company will gear up its effort organically, actively seek mergers and acquisitions of medical projects, and make optimization and integration to offer additional high-quality services to our customers. Looking ahead, the Company will increase the proportion of medical services and proceed with the international business expansion, with a view to becoming a truly multinational medical group." About Perfect Medical Health Management LimitedPerfect Medical Health Management Limited is a multinational aesthetic medical corporate and one of the largest aesthetic medical companies in Hong Kong established in 2003. The Group focuses primarily on non-invasive aesthetic medical services and medical services in Hong Kong, China, Macau, Australia and Singapore with a total service area spanning approximately 322,000 square feet. Our operation offers a broad spectrum of professional services with assurance of utmost safety and efficacy. The Company was included as a constituent stock of the MSCI Hong Kong Small Cap Index on 27 May 2021, demonstrating the confidence of the capital market and recognizing the investment value of the Company. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Fujitsu announces plans to acquire Asia-Pacific’s largest independent ServiceNow consultancy, Enable Professional Services JCN Newswire

Fujitsu announces plans to acquire Asia-Pacific’s largest independent ServiceNow consultancy, Enable Professional Services

TOKYO, Jul 7, 2022 - (JCN Newswire via SEAPRWire.com) - Fujitsu Limited and Fujitsu Australia today announced acquisition plans for Asia-Pacific region's largest independent ServiceNow-specialist, Enable Professional Services. This acquisition continues our approach of using M&A as a tool to support Fujitsu's growth ambitions. Prior to this, Fujitsu Australia acquired data and AI-consultancy, Versor, and Microsoft-specialist, oobe. Enable Professional Services will operate as a stand-alone Fujitsu company for the foreseeable future, under the continued leadership of Bruce Hara. It will be re-branded 'Enable, a Fujitsu company'.With the acquisition of Enable Professional Services, Fujitsu will gain market-leading and award-winning expertise and experience to deliver ServiceNow advisory, consulting, and delivery services for customers across the region. The company's ServiceNow capabilities and digital transformation specialist skills directly support Fujitsu's portfolio transformation and will bolster future offerings for "Business Applications," one of seven Key Focus Areas (KFAs) under Fujitsu's new global Uvance business brand. Enable Professional Services currently operates in Australia, Singapore, Hong Kong, Philippines, and India.Nicholas Fraser, in charge of Strategic Growth & Investments at Fujitsu Limited commented: "M&A helps realize Fujitsu's ambition of becoming a global leading DX services player. We look for opportunities that will help Fujitsu gain differentiation in digital technologies including AI, cybersecurity, or analytics, and build world-class capabilities to engage clients in business transformative discussions. Our investments also accelerate the realization of our Uvance vision. Our planned acquisition of Enable Professional Services represents an important milestone on this journey."Award winning capabilities to accelerate digital transformationFounded in 2014, Enable Professional Services is an award winning ServiceNow Elite partner that builds and implements industry-leading solutions that improve the customer and employee experience, enabling businesses to create value at speed. Through its end-to-end ServiceNow offerings delivered through specialist thought-leading practices, innovative proprietary solutions, and strong people-first culture, Enable Professional Services is leading the way in accelerating digital transformation in the region. The company was distinguished with four ServiceNow awards this year including Asia Pacific and Japan Elite Partner of the Year 2022, an award it has earned in the past three consecutive years for achieving overall excellence in certifications, customer satisfaction and ServiceNow pipeline growth.Yoshinami Takahashi, EVP and Vice Head of Global Solution Business Group, Fujitsu Limited commented, "We are very excited by the prospect of welcoming Enable Professional Services to the Fujitsu Group. Enable Professional Services' capabilities in co-creating value in tandem with Fujitsu's service integration expertise and advanced technologies will play an important role in accelerating our strategy for Business Applications. Fujitsu's vision for Uvance centers on building new possibilities by connecting people, technology and ideas, creating a more sustainable world where anyone can advance their dreams. I am confident that this move will set us on a path to make this vision a reality."Graeme Beardsell, Executive Vice President and CEO, Fujitsu Asia-Pacific, said, "I am delighted that Fujitsu is investing in the growth of Australian technology companies and helping them to expand on a global scale. I look forward to welcoming Enable Professional Services into the Fujitsu family. Enable Professional Services is an impressive force in the market, demonstrating the value and depth of thinking and experience it has to offer for customers on the ServiceNow platform. Together, Fujitsu and Enable Professional Services will accelerate our customers' digital transformations, delivered through our combined deep-industry experience and specialist teams."From an industry perspective, this acquisition will accelerate Fujitsu's experience, depth, and customer base in multiple industries including manufacturing, financial services and telecommunications. The acquisition will actively stimulate growth opportunities for Enable Professional Services' current capabilities into both the local and global markets and provide industry-leading differentiation in ServiceNow services for current Fujitsu customers in Asia-Pacific.Bruce Hara, Chief Executive Officer, Enable Professional Services said, "Enable has always looked for chances to make life better for our customers and for our team. Joining Fujitsu ticks both these boxes, offering us new markets and geographies, and significant scale. With these opportunities, we know we can drive even greater market impact. So the future is exciting, and we're ready to showcase to the world what we can do as a Fujitsu company."About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (USD32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.About Fujitsu Australia and New ZealandFujitsu Australia and New Zealand is a leading service provider of business, information technology and communications solutions. We partner with our customers to consult, design, build, operate and support business solutions. From strategic consulting to application and infrastructure solutions and services, Fujitsu Australia and New Zealand have earned a reputation as the single supplier of choice for leading corporate and government organisations. Fujitsu Australia Limited and Fujitsu New Zealand Limited are wholly owned subsidiaries of Fujitsu Limited (TSE: 6702). See www.fujitsu.com/au.About Enable Professional ServicesEnable Professional Services is an award winning Elite ServiceNow partner with a vision to create opportunities for its teams and customers to do things they've never done before. Enable is a pure-play ServiceNow consultancy, 100% dedicated to the delivery of ServiceNow advisory, consulting and delivery services. With more than 350 consultants and 950+ certifications, Enable are the most qualified, certified and capable ServiceNow partner in the APJ region. Enable have dedicated practices of certified and experienced business consultants across Customer Service Experience, IT Transformation, Employee Service Experience and Integrated Risk Management. Our Principal Consultants and experienced consulting team bring many years of experience in enterprise service management across all modules including HR, GRC, SecOps, CSM, ITOM, ITBM and ITSM. See www.enableps.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More